SPX3,941.26-57.58 -1.44%
DIA336.46-3.57 -1.05%
IXIC11,014.89-225.05 -2.00%

B. Riley Securities Downgrades Infinity Pharmaceuticals to Neutral, Lowers Price Target to $1.5

Benzinga · 11/16/2022 08:02
B. Riley Securities analyst Kalpit Patel downgrades Infinity Pharmaceuticals (NASDAQ:INFI) from Buy to Neutral and lowers the price target from $3 to $1.5.